View on Pubmed.gov 27860216 | View on doi.org 10.1002/ajmg.c....
Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.
Abstract
The phosphatidylinositol-3-kinase (PI3K)/AKT/mTOR signaling pathway plays an essential role in regulation of normal cell growth, metabolism, and survival. Somatic activating mutations in the PI3K/AKT/mTOR pathway are among the most common mutations identified in cancer, and have been shown to cause a spectrum of overgrowth syndromes including PIK3CA-Related Overgrowth Spectrum, Proteus syndrome, and brain overgrowth conditions. Clinical findings in these disorders may be isolated or multiple, including sporadic or mosaic overgrowth (adipose, skeletal, muscle, brain, vascular, or lymphatic), and skin abnormalities (including epidermal nevi, hyper-, and hypopigmented lesions), and have the potential risk of tumorigenesis. Key negative regulators of the PI3K-AKT signaling pathway include PTEN and TSC1/TSC2 and germline loss-of function mutations of these genes are established to cause PTEN Hamartoma Tumor Syndrome and Tuberous Sclerosis Complex. Mosaic forms of these conditions lead to increased activation of PI3K and mTOR at affected sites and there is phenotypic overlap between these conditions. All are associated with significant morbidity with limited options for treatment other than symptomatic therapies and surgeries. As dysregulation of the PI3K/AKT/mTOR pathway has been implicated in cancer, several small molecule inhibitors targeting different components of the PI3K/AKT/mTOR signaling pathway are under clinical investigation. The development of these therapies brings closer the prospect of targeting treatment for somatic PI3K/AKT/mTOR-related overgrowth syndromes. This review describes the clinical findings, gene function and pathogenesis of these mosaic overgrowth syndromes, and presents existing and future treatment strategies to reduce or prevent associated complications of these disorders. © 2016 Wiley Periodicals, Inc.
References
Exp Neurol. 2013 Jun;244:22-6
Hum Mol Genet. 2015 Apr 1;24(7):1836-42
N Engl J Med. 2013 May 23;368(21):1971-9
PLoS One. 2015 Apr 27;10(4):e0123092
Cited by 236 citations (total)
Journal Article
The PI3K/mTOR Pathway Is Targeted by Rare Germline Variants in Patients with Both Melanoma and Renal Cell Carcinoma.
Electronic publication date June 3, 2021
Jean-Noël Hubert [...] Estelle Chanudet et al.
Background: Malignant melanoma and RCC have different embryonic origins, no common lifestyle risk factors but intriguingly share biological properties such...
Journal Article
Silibinin Regulates Tumor Progression and Tumorsphere Formation by Suppressing PD-L1 Expression in Non-Small Cell Lung Cancer (NSCLC) Cells.
Electronic publication date July 3, 2021
Alexis Rugamba [...] Kyoung-Jin Jang et al.
Recently, natural compounds have been used globally for cancer treatment studies. Silibinin is a natural compound extracted from (milk...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
- •
Substances
- •
- •
- •
Copyright
© 2016 Wiley Periodicals, Inc.